Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy
Authors:
- Saye KhooSKSaye Khoo
- A Sarah WalkerAWA Sarah Walker
- Francis SsaliFSFrancis Ssali
- Paula MunderiPMPaula Munderi
- Letitia NamaleLNLetitia Namale
- Andrew ReidARAndrew Reid
- Diana M GibbDGDiana M Gibb
- Peter MugyenyiPMPeter Mugyenyi
- Heiner GrosskurthHGHeiner Grosskurth
- 30 March 2007
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (6) , 733-737
Abstract
Objective: To measure nevirapine elimination in African adults undertaking a structured treatment interruption (STI) in the DART trial. Design: Cohort (16 women, 5 men; median weight 61 kg) within a randomized trial of management strategies. Methods: Plasma nevirapine was measured by validated high performance liquid chromatography at 0,1,2,3 and 4 weeks after stopping the drug in a subset of patients undertaking an STI. All patients continued lamivudine plus zidovudine/stavudine for a further 7 days. Results: Two patients with no or low plasma nevirapine concentration at baseline were excluded. Geometric mean plasma concentration when nevirapine was stopped in the remaining 19 patients was 6421 ng/ml (range, 3724–9473). Nevirapine was detected in 15/18 (83%) patients at 1 week, and 5/19 (26%) patients at 2 weeks but was not found any samples collected after 2 weeks. Only one patient had > 100 ng/ml (limit of quantification) at 2 weeks (415 ng/ml, female). The median times to reach thresholds of 200, 100 and 20 ng/ml (limit of detection) were estimated to be 7.6 [interquartile range (IQR), 7.0–10.1], 9.3 (IQR, 8.7–13.0) and 13.2 (IQR, 12.3–18.4) days, respectively, with 3/19 (16%) and 14/19 (74%) estimated to have reached < 20 ng/ml by 7 and 14 days, respectively. Conclusion: Although elimination of nevirapine was faster than previously published after a single dose, the data suggest that an additional staggered period of 7–10 days with dual nucleotide reverse transcriptase inhibitor cover is necessary for African patients discontinuing nevirapine.Keywords
This publication has 10 references indexed in Scilit:
- Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group StudyClinical Infectious Diseases, 2006
- Anti-Human Immunodeficiency Virus Type 1 Activity of the Nonnucleoside Reverse Transcriptase Inhibitor GW678248 in Combination with Other Antiretrovirals against Clinical Isolate Viruses and In Vitro Selection for ResistanceAntimicrobial Agents and Chemotherapy, 2005
- Nevirapine Plasma Concentrations are Still Detectable After More Than 2 Weeks in the Majority of Women Receiving Single-Dose NevirapineJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn StudyAntiviral Therapy, 2005
- Clinical implications of stopping nevirapine‐based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistanceHIV Medicine, 2004
- Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trialAIDS, 2003
- Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic ParametersThe Journal of Infectious Diseases, 2003
- High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsAIDS, 2001
- Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteersBiopharmaceutics & Drug Disposition, 1999
- High-Dose Nevirapine: Safety, Pharmacokinetics, And Antiviral Effect In Patients With Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1995